FDA approved lisocabtagene maraleucel for adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a BTKi.
fda.gov/drugs/resource…
#OCENewsBurst
🚨 BREAKING! 🚨 Liso-cel is now approved by the U.S. FDA for the treatment of relapsed or refractory #MCL , according to a press release from Bristol Myers Squibb.
Liso-cel 'offers an important new CAR-T treatment option,' said Michael Wang, MD of MD Anderson Cancer Center.
📰 buff.ly/4bWov9G
Hello friends🔻🇵🇸
#freepalestin
Today I'm implementing more services for the workspace module
Organizing & refractory my front-end code as well!
What about you? What are you working on?
- Dm for all your suspended account recovery & device unlock.
Dear Colleagues,
The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 for #Leukemia
This List Curated by Fadi Haddad, MD 🇺🇸 and Gil Morgan, MD 🇺🇸
Abstract #6504: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory
Luminal Strictures
▪️Benign vs. malignant
▪️Simple vs. complex
▪️How to estimate lumen size
▪️When to suspect complications
▪️“Rule of 3s”
▪️👀post-dilation heartburn
▪️French scale
▪️Definition of refractory & recurrent
▪️Endpoints 🥅
▪️Types of dilators & adjuncts
#GITwitter
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research #Myeloma #Biomarkers #ASCO24
doi.org/10.1158/1078-0…
#Chicago #ASCO24 #MoffittASCO24 In this abstract we report data on triplet combination #immunotherapy in a heavily pretreated #PD1 refractory #melanoma population with #Interleukin2 #AntiCTLA4 & #AntiPD1 Moffitt Cancer Center Moffitt Research
meetings.asco.org/abstracts-pres…
Interested in #Endohepatology ?
Swing by the ASGE GI Endoscopy Video plenary session for a novel technique to manage refractory hepatic encephalopathy
Ballroom C, Monday 2pm
#DDW2024